Platinum Priority – EditorialReferring to the article published on pp. 57–62 of this issueImproving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?
Section snippets
Conflicts of interest
G. Sonpavde: grants to institution—Boehringer-Ingelheim, Bayer, Onyx-Amgen, Pfizer, and Merck; consultant for Pfizer, Genentech, Novartis, Argos, Merck, Sanofi, Astellas/Agensys, Clinical Care Options, Astrazeneca, Biotheranostics, Exelixis, Bristol-Myers-Squibb, Janssen, Amgen, and Eisai; speaker/author for Uptodate, National Comprehensive Cancer Network (NCCN), Physicians Education Resource (PER), Onclive, and Research to Practice (RTP). G. Dranitsaris: advisory board—Bristol-Myers-Squibb. A.
References (12)
- et al.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Lancet
(2016) - et al.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Lancet Oncol
(2017) - et al.
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Lancet Oncol
(2018) - et al.
Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer
Eur Urol
(2018) - et al.
How to model survival in cost-effectiveness analysis?. differences between Markov and partitioned survival analysis models
Value Health
(2015) - et al.
Pembrolizumab as second-line therapy for advanced urothelial carcinoma
N Engl J Med
(2017)
Cited by (3)
Multiomics analysis of tumor mutational burden across cancer types
2021, Computational and Structural Biotechnology JournalCitation Excerpt :Compared with those receiving traditional treatment, patients receiving immune checkpoint inhibitor (ICI) treatment may achieve long-term survival. However, ICIs are not effective in all cancer patients [4–6], and most cancer patients treated with ICIs do not benefit. It is vital to determine precise biomarkers to predict the efficacy of immunotherapy.
IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer
2022, Frontiers in Immunology